A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas

Mathematical Biosciences

Volumn 186, Issue 1, 2003, Pages 29-41

  Panetta, John Carl ^a   Kirstein, Mark N ^a,b   Gajjar, A J ^a   Nair, G ^a   Fouladi, M ^a   Stewart, Clinton F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Haemopoiesis; Myelosuppression; Temozolomide

Indexed keywords

MATHEMATICAL MODELS; METABOLISM; PEDIATRICS; TOXICITY; TUMORS;

BONE MARROW;

DRUG THERAPY;

DRUG METABOLITE; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; TEMOZOLOMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CYTOTOXICITY; DRUG BLOOD LEVEL; FEEDBACK SYSTEM; GLIOMA; HEMATOPOIESIS; HUMAN; LEUKOCYTE COUNT; MATHEMATICAL MODEL; MECHANICS; NEGATIVE FEEDBACK; NEUTROPENIA; NEUTROPHIL; PARAMETER; PREDICTION; SIDE EFFECT; STEM CELL;

EID: 0142021064     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mbs.2003.07.002     Document Type: Article

References (20)

1. L.S. Lashford, P. Thiesse, A. Jouvet, T. Jaspan, D. Couanet, P.D. Griffiths, F. Doz, J. Ironside, K. Robson, R. Hobson, M. Dugan, A.D. Pearson, G. Vassal, D. Frappaz, Temozolomide in malignant gliomas of childhood: A united kingdom children's cancer study group and French society for pediatric oncology intergroup study, J. Clin. Oncol. 20 (2002) 4684.
2. L.A. Hammond, J.R. Eckardt, S.D. Baker, S.G. Eckhardt, M. Dugan, K. Forral, P. Reidenberg, P. Statkevich, G.R. Weiss, D.A. Rinaldi, D.D. Von Hoff, E.K. Rowinsky, Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies, J. Clin. Oncol. 17 (1999) 2604.
3. M.N. Kirstein, A.J. Gajjar, J.C. Panetta, D.C. Bowers, S. Thompson, G. Nair, M. Fouladi, R.L. Heideman, C.F. Stewart, Pharmacodynamics (PD) of temozolomide (TMZ) and MTIC in children with high-grade gliomas, Proc. Amer. Soc. Clin. Oncol. 20 (2001).
4. C. Haurie, D.C. Dale, M.C. Mackey, Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models, Blood 92 (1998) 2629.
5. H. Minami, Y. Sasaki, N. Saijo, T. Ohtsu, H. Fujii, T. Igarashi, K. Itoh, Indirect-response model for the time course of leukopenia with anticancer drugs, Clin. Pharmacol. Ther. 64 (1998) 511.
6. S.I. Rubinow, J.L. Lebowitz, A mathematical model of neutrophil production and control in normal man, J. Math. Biol. 1 (1975) 187.
7. T.H. Price, G.S. Chatta, D.C. Dale, Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans, Blood 88 (1996) 335.
8. M.C. Mackey, Mathematical models of hematopoietic cell replication and control, in: H. Othmer, F. Adler, M. Lewis, J. Dallon (Eds.), The Art of Mathematical Modeling: Case Studies in Ecology, Physiology, and Biofluids, Prentice Hall, 1996, p. 149.
9. N. MacDonald, Models of haemopoiesis, Lecture Notes in Biomathematics 27 (1978) 76.
10. M.C. Mackey, L. Glass, Oscillation and chaos in physiological control systems, Science 197 (1977) 287.
11. J.G. Milton, M.C. Mackey, Periodic haematological diseases: mystical entities or dynamical disorders? J. R. Coll. Physicians Lond. 23 (1989) 236.
12. C. Haurie, D.C. Dale, M.C. Mackey, Occurrence of periodic oscillations in the differential blood counts of congenital, idiopathic, and cyclical neutropenic patients before and during treatment with G-CSF, Exp. Hematol. 27 (1999) 401.
13. T. Hearn, C. Haurie, M.C. Mackey, Cyclical neutropenia and the peripheral control of white blood cell production, J. Theor. Biol. 192 (1998) 167.
14. L.E. Friberg, A. Freijs, M. Sandstrom, M.O. Karlsson, Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats, J. Pharmacol. Exp. Ther. 295 (2000) 734.
15. W.C. Zamboni, D.Z. D'Argenio, C.F. Stewart, T. MacVittie, B.J. Delauter, A.M. Farese, D.M. Potter, N.M. Kubat, D. Tubergen, M.J. Egorin, Pharmacodynamic model of topotecan-induced time course of neutropenia, Clin. Cancer Res. 7 (2001) 2301.
16. E.S. Newlands, M.F. Stevens, S.R. Wedge, R.T. Wheelhouse, C. Brock, Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials, Cancer Treat. Rev. 23 (1997) 35.
17. C.M. Kearns, W.C. Wang, N. Stute, J.N. Ihle, W.E. Evans, Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia, J. Pediatr. 123 (1993) 471.
18. J.C. Panetta, M.N. Kirstein, A. Gajjar, G. Nair, M. Fouladi, R.L. Heideman, M. Wilkinson, C.F. Stewart, Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors, Cancer Chemother. Pharmacol. (2003).
19. L.E. Friberg, A. Henningsson, H. Maas, L. Nguyen, M.O. Karlsson, Model of chemotherapy-induced myelosuppression with parameter consistency across drugs, J. Clin. Oncol. 20 (2002) 4713.
20. N. Sawai, S. Zhou, E.F. Vanin, P. Houghton, T.P. Brent, B.P. Sorrentino, Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector, Mol. Ther. 3 (2001) 78.